Marker Therapeutics (MRKR) AML Trial Expected to Begin in 2021 - Roth Capital
Tweet Send to a Friend
Roth Capital analyst Tony Butler reiterated a Buy rating and $6.00 price target on Marker Therapeutics (NASDAQ: MRKR) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
